Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

NCT02117362 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL: 1 mg/kg GR-MD-02
BIOLOGICAL: 2 mg/kg GR-MD-02
BIOLOGICAL: 4 mg/kg GR-MD-02
BIOLOGICAL: 8 mg/kg GR-MD-02
BIOLOGICAL: Ipilimumab

Sponsor

Providence Health & Services

Collaborators

[object Object]
[object Object]